Biogen Inc. (Nasdaq: BIIB) and RayThera Inc., a private biotechnology company focused on discovering and developing small molecule therapies in immunology, announce the companies have entered into a definitive agreement under which Biogen has agreed to acquire RayThera Inc. for up to $1 billion, consisting of an upfront payment and, predominantly, payments contingent on the achievement of future clinical and regulatory milestones. RayThera’s portfolio includes multiple anti-inflammatory assets that could potentially treat immune-mediated conditions across a range of indications. The lead candidate is expected to enter Phase 1 development in early Q3 2026.
Read the full article: Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. //
Source: https://www.globenewswire.com/news-release/2026/06/17/3313870/0/en/biogen-expands-immunology-pipeline-with-agreement-to-acquire-raythera-inc.html